U.S. Markets closed

Should You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility?

Simply Wall St

If you own shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks are more sensitive to general market forces than others. Beta is a widely used metric to measure a stock's exposure to market risk (volatility). Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. The first thing to understand about beta is that the beta of the overall market is one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

See our latest analysis for Pacira BioSciences

What does PCRX's beta value mean to investors?

Given that it has a beta of 1.13, we can surmise that the Pacira BioSciences share price has been fairly sensitive to market volatility (over the last 5 years). If this beta value holds true in the future, Pacira BioSciences shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. Beta is worth considering, but it's also important to consider whether Pacira BioSciences is growing earnings and revenue. You can take a look for yourself, below.

NasdaqGS:PCRX Income Statement, July 31st 2019

Does PCRX's size influence the expected beta?

Pacira BioSciences is a small cap stock with a market capitalisation of US$1.9b. Most companies this size are actively traded. It's not particularly surprising that it has a higher beta than the overall market. That's because it takes less money to influence the share price of a smaller company, than a bigger company.

What this means for you:

Since Pacira BioSciences has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. This article aims to educate investors about beta values, but it's well worth looking at important company-specific fundamentals such as Pacira BioSciences’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for PCRX’s future growth? Take a look at our free research report of analyst consensus for PCRX’s outlook.
  2. Past Track Record: Has PCRX been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of PCRX's historicals for more clarity.
  3. Other Interesting Stocks: It's worth checking to see how PCRX measures up against other companies on valuation. You could start with this free list of prospective options.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.